Eli Lilly''s quarter wasn''t the cleanest but key drug updates speak to its robust pipeline
Eli Lilly''s type-2 diabetes drug is off to a fast start, and the FDA agrees to put Lilly''s Alzheimer''s drug on an accelerated approval pathway.
Eli Lilly''s quarter wasn''t the cleanest but key drug updates speak to its robust pipeline
Eli Lilly''s type-2 diabetes drug is off to a fast start, and the FDA agrees to put Lilly''s Alzheimer''s drug on an accelerated approval pathway.